Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Swedish Orphan Biovitrum and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Swedish Orphan Biovitrum | 20.67% | 17.92% | 9.30% |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Swedish Orphan Biovitrum and AbCellera Biologics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Swedish Orphan Biovitrum | 0 | 3 | 5 | 0 | 2.62 |
| AbCellera Biologics | 1 | 1 | 7 | 2 | 2.91 |
AbCellera Biologics has a consensus price target of $16.20, suggesting a potential upside of 42.54%. Given AbCellera Biologics’ stronger consensus rating and higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Swedish Orphan Biovitrum.
Institutional and Insider Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Swedish Orphan Biovitrum and AbCellera Biologics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Swedish Orphan Biovitrum | $2.89 billion | 6.30 | $48.85 million | $2.01 | 25.40 |
| AbCellera Biologics | $67.85 million | 51.35 | -$146.41 million | ($0.48) | -23.68 |
Swedish Orphan Biovitrum has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Swedish Orphan Biovitrum has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Summary
AbCellera Biologics beats Swedish Orphan Biovitrum on 8 of the 15 factors compared between the two stocks.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
